CYP19A1 and breast cancer: However, aromatase inhibitors (steroidal: exemestane, non-steroidal: anastrozole and letrozole) have largely replaced TAM in the treatment of postmenopausal BC patients due to better efficacy and fewer toxicities, such as the induction of uterine cancer or thromboembolic events [8,9].